U.S. flag

An official website of the United States government

Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 5 books (44 items)

  • The following term was not found in Books: NM_006218.1:c.1633G>A.
  • Quoted phrase not found.
  • See the search details.
1.
PDQ Cancer Information Summaries [Internet].

PDQ Cancer Information Summaries [Internet].

Bethesda (MD): National Cancer Institute (US); 2002-.

Table of Contents

2.
Capivasertib (Truqap): Indication: Capivasertib is indicated in combination with fulvestrant for the treatment of adult females with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy: CADTH Reimbursement Recommendation [Internet].

Capivasertib (Truqap): Indication: Capivasertib is indicated in combination with fulvestrant for the treatment of adult females with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy: CADTH Reimbursement Recommendation [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Sep.

Table of Contents

3.
Alpelisib (Piqray): CADTH Reimbursement Recommendation: Indication: In combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen with a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor [Internet].

Alpelisib (Piqray): CADTH Reimbursement Recommendation: Indication: In combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen with a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Feb.

Table of Contents

4.
Sacituzumab Govitecan (Trodelvy): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+, or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting [Internet].

Sacituzumab Govitecan (Trodelvy): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+, or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Feb.

Table of Contents

5.
CADTH Reimbursement Reviews and Recommendations.

CADTH Reimbursement Reviews and Recommendations.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013-.

Table of Contents

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Search details

See more...

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...